An Open-Label Randomized 2-Period 2-Sequence Crossover Study Comparing Pharmacokinetics Of ABT-494 From The Immediate-Release And Extended-Release Formulations Following Multiple-Dose Administration In Healthy Subjects.
Latest Information Update: 14 May 2018
At a glance
- Drugs Upadacitinib (Primary) ; Upadacitinib
- Indications Atopic dermatitis; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 26 Jan 2017 New trial record